In an article published on Thursday, StockNews.com was the first media outlet to break the news regarding Evolent Health (NYSE: EVH).
The recommendation from the investment firm to “sell” shares of the technology company was carried out.
Evolent Health (NYSE: EVH) made the quarterly financial data it had previously compiled available for public consumption on Wednesday, February 22.
Earnings per share for the quarter at the information technology company came in at $0.04, which was $0.02 less than the consensus forecast of $0.02 per share.
The return on equity for Evolent Health was 7.50 percent, while the net margin for the company was 1.42 percent.
The revenue the company brought in during the quarter was $382.43 million, which is higher than the forecasted amount of $373.68 million that it would bring in during the period.
Evolent Health is expected to generate earnings of $0.23 per share during the current fiscal year, according to projections made by financial analysts.
NYSE: EVH stocks started trading for the first time on Thursday for $30.29 per share.
The stock currently has a simple moving average of $31.88 over the past 50 days, and its simple moving average over the past 200 days is $31.28.
The company’s market capitalization is $3.36 billion, the price-to-earnings ratio is 151.44, and the beta value is 1.56.
The company presently has a debt-to-equity ratio of 0.48, a current ratio of 1.10, and a quick ratio of 1.10. Over the previous twelve months, the cost of Evolent Health has fluctuated between the ranges of $21.83 and $39.78 at various points.
Reports concerning the company in question have also been written by several other analysts employed in the equity research field.
In a research note released on Friday, January 6, Piper Sandler stated that they would be increasing their target price for Evolent Health from $44.00 to $51.00.
This increase came as a result of the company’s recent performance. On Friday, November 18, Cowen released a research note that increased their price objective for Evolent Health from $52.00 to $57.00 and rated the stock as “outperform.” On Monday, January 30, Cowen released a research report stating that they had increased their price objective for Evolent Health from $57.00 to $59.00 and that they rated the company as “outperforming.” Royal Bank of Canada reaffirmed an “outperform” rating on shares of Evolent Health and positioned them with a $44.00 price objective in research made public on Thursday, February 23.
The report was about the company’s stock.
The price objective that BTIG Research has set for Evolent Health has increased from $40.00 to $45.00 due to a research report published on Thursday, February 23. One of the experts recommended buying the stock, nine strongly encouraged buying the stock, and the remaining expert simply recommended holding on to the stock.
The data compiled by Bloomberg indicates that the standard recommendation for Evolent Health is a “Moderate Buy” and that the price target for the company is currently set at $47.70.
On March 1, Director Frank J. Williams sold 110,000 shares of the company’s stock, which brings us to another piece of news.
This sale was mentioned in another piece of recent news.
A total transaction of 3,847,800.00 worth of the stock took place at an average price of $34.98 per share.
Because of the sale, the director owns 626,479 company shares, and the total value is approximately $21,914,235.42.
If you click on this link, you will be taken to a legal filing made with the SEC, which will give you more information regarding the transaction and take you there immediately.
The announcement that director Frank J. Williams had sold 90,356 shares of the company’s stock was one of the other pieces of news published on Monday, March 6.
There was 3,110,053.52 worth of transactions involving company stock shares, completed at an average price of $34.42 per share.
After completing the transaction involving those shares, the director now owns 936,123 of the company’s shares, which are approximately $32,221,353.66. One can find a copy of the case file in which the transaction was disclosed on the Securities and Exchange Commission (SEC) website.
The file contains information about the transaction.
The transaction to sell 110,000 shares occurred on March 1 and was completed by Frank J. Williams, a company director.
A total of $3,847,800.00 was received for the sale of the shares, which works out to a price of $34.98 per share on average. Following the completion of the transaction, the director now owns 626,479 shares of the company.
The current market value of these shares is $21,914,235.42.
Disclosures related to the sale might be found in this website section.
Insiders of the company have sold 384,284 shares of stock over the most recent ninety days, resulting in a total profit of $12,488,955 for the business. 4.20 company insiders own a percent of the total shares currently outstanding.
The percentages of the company’s stock that significant investors own have undergone recent shifts due to recent transactions.
In the third quarter, Altshuler Shaham Ltd opened a new holding, which resulted in the company investing in Evolent Health with a total value of $25,000.
A financial investment of $32,000 was made in Evolent Health by ICA Group Wealth Management LLC during the final three months of 2018.
During the third quarter, C.M.
Bidwell & Associates Ltd provided Evolent Health with an investment of $33,000 in the capital. Hollencrest Capital Management spent $42,000 during the fourth quarter to acquire a new stake in Evolent Health.
This transaction took place during the quarter.
A newly created position at Evolent Health required a fee of $54,000 during the fourth quarter, which was paid for by Van ECK Associates Corp.
At present, hedge funds and other institutional investors own 93.33% of the company’s shares.